Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
141.84
+0.14 (0.10%)
At close: Dec 18, 2025, 4:00 PM EST
134.32
-7.52 (-5.30%)
After-hours: Dec 18, 2025, 7:22 PM EST
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 21 analysts that cover Neurocrine Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $176.19, which forecasts a 24.22% increase in the stock price over the next year. The lowest target is $115 and the highest is $203.
Price Target: $176.19 (+24.22%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 10 | 10 | 12 |
| Buy | 10 | 8 | 7 | 7 | 7 | 7 |
| Hold | 2 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 19 | 17 | 18 | 18 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $168 → $198 | Strong Buy | Maintains | $168 → $198 | +39.59% | Dec 17, 2025 |
| Mizuho | Mizuho | Hold Maintains $146 → $175 | Hold | Maintains | $146 → $175 | +23.38% | Dec 12, 2025 |
| Stifel | Stifel | Strong Buy Maintains $183 → $188 | Strong Buy | Maintains | $183 → $188 | +32.54% | Dec 11, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $160 → $180 | Buy | Maintains | $160 → $180 | +26.90% | Dec 8, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $175 → $200 | Strong Buy | Maintains | $175 → $200 | +41.00% | Dec 5, 2025 |
Financial Forecast
Revenue This Year
2.92B
from 2.36B
Increased by 23.76%
Revenue Next Year
3.44B
from 2.92B
Increased by 18.01%
EPS This Year
5.14
from 3.29
Increased by 56.20%
EPS Next Year
6.89
from 5.14
Increased by 34.01%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.0B | 3.8B | ||||
| Avg | 2.9B | 3.4B | ||||
| Low | 2.8B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 28.6% | 31.5% | ||||
| Avg | 23.8% | 18.0% | ||||
| Low | 17.1% | 4.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 5.82 | 9.45 | ||||
| Avg | 5.14 | 6.89 | ||||
| Low | 4.46 | 3.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 76.8% | 83.9% | ||||
| Avg | 56.2% | 34.0% | ||||
| Low | 35.5% | -31.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.